These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 1431308

  • 1. Different interactions of interferon-alpha subtypes at the surface of epithelial and lymphoid cells.
    Overall ML, Chambers P, Hertzog PJ.
    J Interferon Res; 1992 Aug; 12(4):281-8. PubMed ID: 1431308
    [Abstract] [Full Text] [Related]

  • 2. Functional analysis of interferon-alpha subtypes using monoclonal antibodies to interferon-alpha 4a--subtype reactivity, neutralisation of biological activities and epitope analysis.
    Overall ML, Hertzog PJ.
    Mol Immunol; 1992 Mar; 29(3):391-9. PubMed ID: 1372957
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Studies on the antitumor activity of human recombinant interferon alpha-2b in vitro].
    Haraguchi S, Koide Y, Matsuo T, Yoshida TO.
    Gan To Kagaku Ryoho; 1986 Oct; 13(11):3236-43. PubMed ID: 2946265
    [Abstract] [Full Text] [Related]

  • 5. A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities.
    Ozes ON, Reiter Z, Klein S, Blatt LM, Taylor MW.
    J Interferon Res; 1992 Feb; 12(1):55-9. PubMed ID: 1573283
    [Abstract] [Full Text] [Related]

  • 6. Localization of the receptor binding site of IFN-alpha 2b.
    Siemers R, Hensley L, Ozer H.
    J Immunol; 1988 Sep 01; 141(5):1550-5. PubMed ID: 2970505
    [Abstract] [Full Text] [Related]

  • 7. Different functional sites on rIFN-alpha 2 and their relation to the cellular receptor binding site.
    Cebrián M, Yagüe E, de Landázuri MO, Rodíguez-Moya M, Fresno M, Pezzi N, Llamazares S, Sánchez-Madrid F.
    J Immunol; 1987 Jan 15; 138(2):484-90. PubMed ID: 2432126
    [Abstract] [Full Text] [Related]

  • 8. Comparative antiproliferative and receptor binding activities of interferons alpha and beta on lymphoblastoid and melanoma cells.
    Hertzog PJ, Johns TG, Callister KA, Dinatale A, Linnane AW.
    Biochem Int; 1990 Dec 15; 22(6):1095-102. PubMed ID: 2151021
    [Abstract] [Full Text] [Related]

  • 9. Identification of residues of the IFNAR1 chain of the type I human interferon receptor critical for ligand binding and biological activity.
    Cajean-Feroldi C, Nosal F, Nardeux PC, Gallet X, Guymarho J, Baychelier F, Sempé P, Tovey MG, Escary JL, Eid P.
    Biochemistry; 2004 Oct 05; 43(39):12498-512. PubMed ID: 15449939
    [Abstract] [Full Text] [Related]

  • 10. Characterization of a domain of a human type I interferon receptor protein involved in ligand binding.
    Eid P, Tovey MG.
    J Interferon Cytokine Res; 1995 Mar 05; 15(3):205-11. PubMed ID: 7584665
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antigenic characterization of recombinant, lymphoblastoid, and leukocyte IFN-alpha by monoclonal antibodies.
    Viscomi GC, Antonelli G, Bruno C, Scapol L, Malavasi F, Funaro A, Simeoni E, Pestka S, De Pisa F, Dianzani F.
    J Interferon Cytokine Res; 1999 Apr 05; 19(4):319-26. PubMed ID: 10334382
    [Abstract] [Full Text] [Related]

  • 13. Characterization of the binding of radioiodinated hybrid recombinant IFN-alpha A/D to murine and human lymphoid cell lines.
    Faltynek CR, Princler GL, Schwabe M, Shata MT, Lewis GK, Kamin-Lewis RM.
    J Interferon Res; 1990 Feb 05; 10(1):55-64. PubMed ID: 2139461
    [Abstract] [Full Text] [Related]

  • 14. Evidence for multiple binding sites for several components of human lymphoblastoid interferon-alpha.
    Hu R, Gan Y, Liu J, Miller D, Zoon KC.
    J Biol Chem; 1993 Jun 15; 268(17):12591-5. PubMed ID: 8509399
    [Abstract] [Full Text] [Related]

  • 15. Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon beta.
    Johns TG, Mackay IR, Callister KA, Hertzog PJ, Devenish RJ, Linnane AW.
    J Natl Cancer Inst; 1992 Aug 05; 84(15):1185-90. PubMed ID: 1378904
    [Abstract] [Full Text] [Related]

  • 16. Interferon-beta and recombinant IL 2 can both enhance, but by different pathways, the nonspecific cytolytic potential of T3- natural killer cell-derived clones rather than that of T3+ clones.
    van de Griend RJ, Ronteltap CP, Gravekamp C, Monnikendam D, Bolhuis RL.
    J Immunol; 1986 Mar 01; 136(5):1700-7. PubMed ID: 3005399
    [Abstract] [Full Text] [Related]

  • 17. Localization of a receptor nonapeptide with a possible role in the binding of the type I interferons.
    Eid P, Langer JA, Bailly G, Lejealle R, Guymarho J, Tovey MG.
    Eur Cytokine Netw; 2000 Dec 01; 11(4):560-73. PubMed ID: 11125298
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Binding of human alpha-interferons to natural killer cells.
    Langer JA, Ortaldo JR, Pestka S.
    J Interferon Res; 1986 Apr 01; 6(2):97-105. PubMed ID: 2941494
    [Abstract] [Full Text] [Related]

  • 20. Differential neutralizing activity of human antibodies in interferon antiviral and natural killer cell bioassays.
    Thurmond LM, Reese MJ.
    J Interferon Cytokine Res; 1997 Oct 01; 17(10):619-23. PubMed ID: 9355963
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.